PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: *William M. Hammesfahr*

S.N.: **09/841,546** GROUP ART UNIT 3737

FILED: **04/23/2001** EXAMINER: Ramirez, John F.

FOR: **A TITRATION SYSTEM FOR TREATING CEREBRAL VASOSPASMS** ATTY. DOC. **2087.1**

_____/

MAIL STOP APPEAL BRIEF – PATENTS
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Sir:

APPLICANT'S BRIEF ON APPEAL

In response to the Notice of Non-Compliant Appeal Brief, dated June 26, 2008, applicant submits three copies of the amended Claims Appendix in substitution of the previously filed Claims Appendix which contained a typographical error in Claim 43.

Respectfully submitted,

/Herbert William Larson/

Herbert W. Larson
Registration No. 21008
Attorney for Applicant
LARSON & LARSON, PA
11199 69th Street North
Largo, FL 33773
(727) 546-0660 Phone
(727) 545-1595 Fax

Customer No. 22497

VIII. CLAIMS APPENDIX

38. A titration system for diagnosing and treating a disease caused at least partially by insufficient cerebral perfusion, comprising in combination:

a flow measuring device to test for cerebral vasospasm, a dosage device which administers a vasospasm-reducing dosage of a medicine selected from the empirical group of medications which have the common characteristic of causing smooth muscle relaxation and/or which reduce pulmonary capillary wedge pressure, and said dosage device being adjustable over time to titrate said dosage in response to said testing to increase, decrease or substitute another medicine to minimize occurrence and severity of said vasospam.

39. A system according to Claim 38 wherein the flow measuring device comprises transcranial Doppler measuring means.

40. A system according to Claim 38 wherein the dosage device comprises means for delivering a vasodilator selected from the group comprising Nitroglycerin in pill, patch, ointment, cream, inhaler, spray and other forms, Nitroglycerin equivalents and substitutes, comprising p.o. clonidine, israpidine, hydrazine, nifedipine, and/or other medicines selected from the empirical

group of medications which have the common characteristic of causing smooth muscle relaxation and/or which systemically reduce pulmonary capillary wedge pressure, and combinations of the foregoing.

41. A system according to Claim 38 wherein the flow measuring device comprises transcranial Doppler measuring means and the dosage device comprises transdermal, inhaler, spray and other forms of vasodilator selected from the group consisting of Nitroglycerin, Nitroglycerin equivalents and substitutes, p.o. clonidine, isradipine, hydrazine, nifedipine, and/or medicines selected from the empirical group of medications which have the common characteristic of causing smooth muscle relaxation and/or which systemically reduce pulmonary capillary wedge pressure, and combinations of the foregoing.

42. A system according to Claim 41 wherein the delivery device comprises means for delivering a vasodilator selected from the group comprising Nitroglycerin in pill, patch, ointment or cream form.

43. A system according to Claim [46] 41 wherein the delivery system is adapted for transdermal delivery.

44. A system according to Claim 38 wherein the delivery system is adapted for the adjusting of the dosage device over time within the range of about 0.02 to 20 milligrams per day (Nitroglycerin equivalent) of vasodilator.

VIII. CLAIMS APPENDIX

38. A titration system for diagnosing and treating a disease caused at least partially by insufficient cerebral perfusion, comprising in combination:

a flow measuring device to test for cerebral vasospasm, a dosage device which administers a vasospasm-reducing dosage of a medicine selected from the empirical group of medications which have the common characteristic of causing smooth muscle relaxation and/or which reduce pulmonary capillary wedge pressure, and said dosage device being adjustable over time to titrate said dosage in response to said testing to increase, decrease or substitute another medicine to minimize occurrence and severity of said vasospam.

39. A system according to Claim 38 wherein the flow measuring device comprises transcranial Doppler measuring means.

40. A system according to Claim 38 wherein the dosage device comprises means for delivering a vasodilator selected from the group comprising Nitroglycerin in pill, patch, ointment, cream, inhaler, spray and other forms, Nitroglycerin equivalents and substitutes, comprising p.o. clonidine, israpidine, hydrazine, nifedipine, and/or other medicines selected from the empirical

group of medications which have the common characteristic of causing smooth muscle relaxation and/or which systemically reduce pulmonary capillary wedge pressure, and combinations of the foregoing.

41. A system according to Claim 38 wherein the flow measuring device comprises transcranial Doppler measuring means and the dosage device comprises transdermal, inhaler, spray and other forms of vasodilator selected from the group consisting of Nitroglycerin, Nitroglycerin equivalents and substitutes, p.o. clonidine, isradipine, hydrazine, nifedipine, and/or medicines selected from the empirical group of medications which have the common characteristic of causing smooth muscle relaxation and/or which systemically reduce pulmonary capillary wedge pressure, and combinations of the foregoing.

42. A system according to Claim 41 wherein the delivery device comprises means for delivering a vasodilator selected from the group comprising Nitroglycerin in pill, patch, ointment or cream form.

43. A system according to Claim [46] 41 wherein the delivery system is adapted for transdermal delivery.

44. A system according to Claim 38 wherein the delivery system is adapted for the adjusting of the dosage device over time within the range of about 0.02 to 20 milligrams per day (Nitroglycerin equivalent) of vasodilator.

VIII. CLAIMS APPENDIX

38. A titration system for diagnosing and treating a disease caused at least partially by insufficient cerebral perfusion, comprising in combination:

a flow measuring device to test for cerebral vasospasm, a dosage device which administers a vasospasm-reducing dosage of a medicine selected from the empirical group of medications which have the common characteristic of causing smooth muscle relaxation and/or which reduce pulmonary capillary wedge pressure, and said dosage device being adjustable over time to titrate said dosage in response to said testing to increase, decrease or substitute another medicine to minimize occurrence and severity of said vasospam.

39. A system according to Claim 38 wherein the flow measuring device comprises transcranial Doppler measuring means.

40. A system according to Claim 38 wherein the dosage device comprises means for delivering a vasodilator selected from the group comprising Nitroglycerin in pill, patch, ointment, cream, inhaler, spray and other forms, Nitroglycerin equivalents and substitutes, comprising p.o. clonidine, israpidine, hydrazine, nifedipine, and/or other medicines selected from the empirical

group of medications which have the common characteristic of causing smooth muscle relaxation and/or which systemically reduce pulmonary capillary wedge pressure, and combinations of the foregoing.

41. A system according to Claim 38 wherein the flow measuring device comprises transcranial Doppler measuring means and the dosage device comprises transdermal, inhaler, spray and other forms of vasodilator selected from the group consisting of Nitroglycerin, Nitroglycerin equivalents and substitutes, p.o. clonidine, isradipine, hydrazine, nifedipine, and/or medicines selected from the empirical group of medications which have the common characteristic of causing smooth muscle relaxation and/or which systemically reduce pulmonary capillary wedge pressure, and combinations of the foregoing.

42. A system according to Claim 41 wherein the delivery device comprises means for delivering a vasodilator selected from the group comprising Nitroglycerin in pill, patch, ointment or cream form.

43. A system according to Claim [46] 41 wherein the delivery system is adapted for transdermal delivery.

44. A system according to Claim 38 wherein the delivery system is adapted for the adjusting of the dosage device over time within the range of about 0.02 to 20 milligrams per day (Nitroglycerin equivalent) of vasodilator.